Navigation Links
Mylan Creates New Women's Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
Date:8/6/2008

PITTSBURGH, Aug. 6 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it has completed an agreement with Famy Care Ltd, a global, India-based manufacturing leader of women's health care products, to develop and supply 22 oral contraceptive (OC) medicines to customers in the United States. The agreement also provides Mylan with a right of first refusal for additional oral contraceptive products and certain additional markets, including Australia and Japan, where Mylan has a significant presence. Terms of the agreement were not disclosed.

"Through our partnership with Famy Care, we have met another longstanding commitment by expanding our portfolio to create a women's health care franchise for Mylan," said Mylan Vice Chairman and CEO Robert J. Coury. "We anticipate filing ANDAs as early as the next few months and beginning to commercialize them in 2010.

"After working on this initiative for some time, we have found an outstanding partner in Famy Care, the world's largest manufacturer of oral contraceptives. Famy Care is a well-established and well-respected global company, deeply committed to quality and customer satisfaction. We're delighted to have completed this agreement with an organization considered a world leader in generic contraceptives, and we look forward to bringing these OC medicines to U.S. customers as quickly as possible."

"We discussed aligning Famy Care with a number of highly qualified companies, but Mylan clearly became the partner-of-choice," said Sanjeev Taparia, Famy Care's managing director. "We based our decision on Mylan's strong presence in the United States, expanded global commercial footprint and its high quality and customer service standards. Mylan is well-positioned to help us achieve the vast potential we see in our diverse women's health care product portfolio."

Currently, total U.S. OC market sales are approximately $3.3 billion, according to IMS. Of the 42 OC products available, 31 are sold generically. OCs are dispensed primarily in retail pharmacies, although certain clinic channels, such as Planned Parenthood, are important, particularly for new customers.

Based in Mumbai, India, Famy Care manufactures a wide range of reproductive health care products, including oral and emergency contraceptives, intra-uterine devices (IUDs) and tubal ligation rings. Incorporated in 1990, the company exports its products to more than 50 countries on four continents. The company has established strong manufacturing and R&D capabilities with state-of-the-art facilities throughout India.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

This press release includes statements that constitute "forward-looking statements," including with regard to Mylan's agreement with Famy Care and the anticipated ANDA filings and product commercializations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks inherent in product development and regulatory matters; the effect of any changes in customer and supplier relationships and customer purchasing patterns; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the Company's business; and uncertainties and matters beyond the control of management. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the Company or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary statements and risk factors in the Company's Form 10-Q for the quarter ended March 31, 2008, and in its other filings with the SEC. The Company undertakes no obligation to update statements herein for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology: